Rezon Bio Launches as European Biologics CDMO
The Polish company debuts as a European biologics CDMO, offering services from accelerated development through to commercialization using advanced digital tools and mirrored GMP-certified sites.
Building on its legacy in biologics development, Rezon Bio has officially launched as a new European biologics CDMO (1). The CDMO business has launched under a new name, after Polpharma Biologics announced it was splitting into two independent companies (2).
Featuring two state-of-the-art facilities located in Gdańsk and Duchnice-Warsaw, Rezon Bio will offer end-to-end capabilities from cell line development to good manufacturing practice (GMP) manufacturing and commercial supply. Both sites are equipped with mirrored capabilities for seamless technology transfer and flexible scale-up, leveraging single-use systems designed to shorten product turnover times and accelerate delivery (1).
Emphasizing the company’s deep experience in biologics development, CEO Adriana Kiędzierska-Mencfeld highlighted how Rezon Bio aims to simplify and accelerate the biologic development journey for clients while maintaining cost-efficiency. “Rezon Bio is a new name, but it stands on a track record that already includes building a broad biosimilars portfolio — with two products launched worldwide through our partners,” specified Kiędzierska-Mencfeld in a company press release (1). “That experience is the foundation of our new CDMO offering. We know the challenges of developing and launching biologics because we have been through them ourselves. Now we are here to make that journey easier, faster and cost-efficient for our clients.”
Capitalizing on Poland’s strong biopharma talent and competitive cost structure, the company is committed to rigorous global compliance standards through its EMA certification and U.S. FDA approval at the Gdańsk site. Additionally, the company has plans to gain FDA licensing at its already EMA-certified Duchnice-Warsaw facility. Through digital innovation, Rezon Bio will offer integrated process modeling, AI-enabled systems, and project transparency tools to help clients manage timelines, anticipate risks, and maintain comparability, ultimately reducing delays and compressing time to market.
“We will disrupt the European CDMO landscape by being the most cost competitive and reliable partner,” added Konstantin Matentzoglu, Chairman of the Supervisory Board of Rezon Bio, in the press release (1). “Our commitment is to accelerate programs while maximizing customer value that benefits patients worldwide.”
Rezon Bio plans to present its capabilities and leadership at upcoming biomanufacturing and industry events including at CPHI Frankfurt, which will be taking place between Oct. 28–30, 2025.
References
Rezon Bio. Rezon Bio Launches as a European Biologics CDMO Combining Cost Efficiency and Digital Innovation. Press Release, Sep. 29, 2025.
Polpharma Biologics. Polpharma Biologics is Splitting its Operations into Two Independent Companies. Press Release, Sep. 29, 2025.